Articles from Courage Therapeutics

Courage Therapeutics, a company developing novel treatments for genetic and dietary obesity and diseases of wasting, today announced it has closed funding led by Arsenal Bridge Ventures, a venture capital firm specializing in high-impact, early-stage biotech companies, and joined by existing investors. This brings the company’s funding to over $11 million.

Courage Therapeutics, a company at the forefront of developing treatments for obesity and eating disorders, today announced the appointment of Giovanni Ferrara as its Chief Executive Officer. This announcement follows a significant investment earlier in May led by Arsenal Bridge Ventures, which has positioned the company to accelerate development of its promising targeted drug candidates that could further advance the treatment landscape for these conditions.